Gepotidacin 750mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 750mg

Reference Brands: Blujepa (USA)

Category: Antibiotics

Gepotidacin is a novel oral antibiotic belonging to the triazaacenaphthylene class. It works by inhibiting bacterial enzymes DNA gyrase and topoisomerase IV, which are essential for bacterial DNA replication, thereby preventing bacterial growth. Marketed under the brand name Blujepa in the USA, it is available as 750 mg tablets. It is primarily used to treat uncomplicated urinary tract infections (uUTIs) caused by susceptible bacteria in adults and adolescents.

Product Description:

Gepotidacin is a triazaacenaphthylene antibacterial — the first genuinely new class of oral antibiotic approved for uncomplicated urinary tract infection in nearly thirty years. It inhibits bacterial DNA replication by binding two type II topoisomerase enzymes at a site distinct from that used by fluoroquinolones. Because the binding site differs, existing fluoroquinolone resistance does not confer cross-resistance, which is the point of the molecule.

The US FDA approved it in March 2025 for uncomplicated UTI in female adults and adolescents from twelve years, against E. coli, Klebsiella pneumoniae, Citrobacter freundii, Staphylococcus saprophyticus and Enterococcus faecalis. It has since been approved for uncomplicated urogenital gonorrhoea, an indication of considerable public health importance given the narrowing treatment options in Neisseria gonorrhoeae. It is supplied as 750 mg tablets.

Sourcing notes. This is a newly approved, on-patent innovator product from a single manufacturer. No generic exists and none can lawfully exist for years; an offer of generic gepotidacin should be refused and investigated. Approvals outside the United States were still progressing through 2026, so availability is strictly market-dependent. Where a patient in an unapproved market requires it, named-patient import is the mechanism.